|
WO2021055765A2
|
|
Multimeric antibodies with enhanced selectivity for cells with high target density
|
|
WO2021041250A1
|
|
Igm glycovariants
|
|
WO2021030688A1
|
|
Immunostimulatory multimeric binding molecules
|
|
WO2021034646A1
|
|
Multimeric bispecific anti-cd123 binding molecules and uses thereof
|
|
WO2020163646A1
|
|
Anti-gitr antigen-binding domains and uses thereof
|
|
CA3113268A1
|
|
Multivalent igm- and iga-fc-based binding molecules
|
|
SG11202008343YA
|
|
IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
|
|
AU2019224136A1
|
|
Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
|
|
AU2018248336A1
|
|
Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
|
|
EP3487533A1
|
|
Multimeric ox40 binding molecules and uses thereof
|
|
US2019330360A1
|
|
Multimeric gitr binding molecules and uses thereof
|
|
WO2018017761A1
|
|
Multimeric cd137/4-1bb binding molecules and uses thereof
|
|
CA3030640A1
|
|
Multimeric cd40 binding molecules and uses thereof
|
|
CN109311985A
|
|
Anti- PD-L1 antibody
|
|
WO2017059380A1
|
|
Binding molecules with modified j-chain
|
|
CN108463472A
|
|
The binding molecule of J- chains with modification
|
|
US2018118816A1
|
|
Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
|
|
KR20180012245A
|
|
A multivalent hepatitis B virus antigen binding molecule and its use
|
|
CN107532188A
|
|
CD20 binding molecules and application thereof
|
|
AU2016209324A1
|
|
Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
|
